Emergent BioSolutions Inc.: directors' dealings · United States · SEC (Form 4)

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. (ticker EBS) is a U.S.-based life sciences company listed on the NYSE in the United States, with headquarters in Gaithersburg, Maryland. The company built its franchise around public health preparedness and response, with a long-standing focus on medical countermeasures and emergency-use products. Its corporate history is closely tied to BioThrax, the anthrax vaccine that helped establish Emergent’s identity and positioned it as a specialized supplier to government and public-sector customers. The company’s website notes that it began operations partnering with the U.S. government to supply BioThrax, and that its common stock trades on the New York Stock Exchange. ([emergentbiosolutions.com](https://www.emergentbiosolutions.com/our-company/?utm_source=openai)) According to Emergent’s 2025 annual report, the business is now organized around four core product and service categories: anthrax medical countermeasures, naloxone commercial products, smallpox medical countermeasures, and Emergent Bioservices CDMO services. Management describes the company as a global life sciences platform focused on innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring public health threats. It targets several threat areas, including CBRNE, emerging infectious diseases, emerging health crises, and acute, emergency and community care. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm?utm_source=openai)) From an equity analyst perspective, Emergent is a niche, high-barrier business rather than a broad-based pharmaceutical platform. Its competitive position rests on specialized manufacturing capabilities, regulatory know-how, and long-duration relationships with government agencies and commercial partners. That specialization creates strategic value in procurement-driven markets, where trust, compliance, and operational reliability matter as much as product innovation. At the same time, the model carries concentration risk, especially given the importance of a limited number of programs and counterparties. The company disclosed a product portfolio of 11 products, 10 of which are owned, serving government and commercial customers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm?utm_source=openai)) Key products and franchises include BioThrax, naloxone-based emergency products, and smallpox-related countermeasures, alongside contract development and manufacturing services. The CDMO arm is important because it monetizes manufacturing capacity and technical expertise beyond the proprietary product base, offering a secondary growth lever and some revenue diversification. This mix helps explain why Emergent is often viewed as both a biodefense supplier and a specialized manufacturing services provider. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm?utm_source=openai)) Geographically, Emergent remains anchored in the United States, with its headquarters in Maryland and a historically strong reliance on U.S. government demand, while also looking to expand internationally in biodefense and medical countermeasures. In its February 2026 results release, the company said it aimed to expand international penetration in its MCM biodefense business, maintain leadership in naloxone, and pursue organic and inorganic growth opportunities. That release also reported 2025 revenue of $742.9 million, net income of $52.6 million, a return to profitability, the sale of the Baltimore-Bayview facility for $36.5 million, a restarted share repurchase program, and roughly $303 million of announced medical countermeasure contract options. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000012/ebs2025-12x31exhibit99er.htm?utm_source=openai))